Literature DB >> 18171991

Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases.

Stephanie Kreis1, Georg A Munz, Serge Haan, Peter C Heinrich, Iris Behrmann.   

Abstract

Signal transducers and activators of transcriptions (STAT) are key mediators of cytokine signaling. Moreover, these transcription factors play a crucial role in oncogenic signaling where inappropriate and sustained activation of STATs, especially STAT3, is a trait of many different cancers and their derived cell lines. Constitutively active STAT3 has been reported to prevent programmed cell death and enhance cell proliferation, whereas the disruption of STAT3 signaling can inhibit tumor growth. The physiologic activation of STAT3 by cytokines has been well established; however, little is known about altered, stimulation-independent STAT3 activation. Here, we show that, in most but not all melanoma cell lines, STAT3 phosphorylation increased substantially with cell density and that this STAT3 was able to bind to DNA and to activate transcription. Inhibitor studies showed that the cell density-dependent STAT3 activation relies on Janus kinases (JAK) rather than Src kinases. Using a specific JAK inhibitor, sustained STAT3 activation was completely abrogated in all tested melanoma lines, whereas inhibition of Src or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 had no effect on constitutively tyrosine-phosphorylated STAT3 levels. Although STAT3 activation was completely blocked with JAK inhibitor I and to a lesser extent with the common JAK inhibitor AG490, only the latter compound markedly decreased proliferation and induced apoptosis. Taken together, variations in cell density can profoundly modify the extent of JAK-mediated persistent STAT3 phosphorylation; however, STAT3 activation was not sufficient to provide critical growth and survival signals in melanoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18171991     DOI: 10.1158/1541-7786.MCR-07-0317

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  23 in total

Review 1.  The R(h)oads to Stat3: Stat3 activation by the Rho GTPases.

Authors:  Leda Raptis; Rozanne Arulanandam; Mulu Geletu; James Turkson
Journal:  Exp Cell Res       Date:  2011-05-18       Impact factor: 3.905

2.  Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.

Authors:  Pijus K Mandal; Fengqin Gao; Zhen Lu; Zhiyong Ren; Rajagopal Ramesh; J Sanderson Birtwistle; Kumaralal K Kaluarachchi; Xiaomin Chen; Robert C Bast; Warren S Liao; John S McMurray
Journal:  J Med Chem       Date:  2011-04-26       Impact factor: 7.446

3.  Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.

Authors:  Annedore Respa; Juergen Bukur; Soldano Ferrone; Graham Pawelec; Yingdong Zhao; Ena Wang; Francesco M Marincola; Barbara Seliger
Journal:  Clin Cancer Res       Date:  2011-01-19       Impact factor: 12.531

Review 4.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

5.  A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Authors:  Edmond J Auzenne; Jim Klostergaard; Pijus K Mandal; Warren S Liao; Zhen Lu; Fengqin Gao; Robert C Bast; Fredika M Robertson; John S McMurray
Journal:  J Exp Ther Oncol       Date:  2012

6.  12-O-tetradecanoylphorbol-13-acetate inhibits melanoma growth by inactivation of STAT3 through protein kinase C-activated tyrosine phosphatase(s).

Authors:  Masahiro Oka; Naoko Sumita; Masanobu Sakaguchi; Tetsushi Iwasaki; Toshinori Bito; Toshiro Kageshita; Ken-ichi Sato; Yasuo Fukami; Chikako Nishigori
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

7.  Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.

Authors:  Hannes Neuwirt; Martin Puhr; Frédéric R Santer; Martin Susani; Wolfgang Doppler; Gemma Marcias; Veronika Rauch; Maria Brugger; Alfred Hobisch; Lukas Kenner; Zoran Culig
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

Review 8.  Engaged for survival: From cadherin ligation to STAT3 activation.

Authors:  Mulu Geletu; Stephanie Guy; Rozanne Arulanandam; Hélène Feracci; Leda Raptis
Journal:  JAKSTAT       Date:  2013-12-06

9.  Structure-Activity Studies of Phosphopeptidomimetic Prodrugs Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3 (Stat3).

Authors:  Pijus K Mandal; Zhiyong Ren; Xiaomin Chen; Kumar Kaluarachchi; Warren S-L Liao; John S McMurray
Journal:  Int J Pept Res Ther       Date:  2013-03       Impact factor: 1.931

Review 10.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

Authors:  Darryl A Oble; Robert Loewe; Ping Yu; Martin C Mihm
Journal:  Cancer Immun       Date:  2009-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.